Home / People / Fionnuala Rice
Portrait ofFionnuala Rice

Fionnuala Rice

Senior Associate

Contact
CMS Cameron McKenna Nabarro Olswang LLP
Cannon Place
78 Cannon Street
London
EC4N 6AF
United Kingdom
Languages English

Fionnuala is a Senior Associate in the Intellectual Property department, advising on the protection and enforcement of all IP rights.  

Fionnuala has a particular focus on patent litigation, working with a range of clients to bring and defend High Court infringement and validity proceedings, as well as advising on other areas such as co-ownership, licensing and commercialisation.  Fionnuala works closely with the patent attorneys in the IP team, frequently working on projects where dual prosecution and litigation strategies are needed.  

In addition, Fionnuala has an established Regulatory practice, advising clients on the regulation of pharmaceuticals and medical devices at all stages of a product’s lifecycle, including pre-launch activities, product claims and borderline products.  She also advises on data and market exclusivity rights for pharmaceutical products, developing exclusivity strategies and judicial review.

Fionnuala has significant experience in the Life Sciences sector and regularly works on litigation, transactions and strategic advice in this area.  She is Co-Head of the CMS UK Life Sciences Associate Network and a UK representative in the CMS Global Life Sciences & Healthcare Associate Group.

more less

Education

  • 2016 – Postgraduate Diploma in Intellectual Property Law and Practice, University of Oxford
  • 2010 – Legal Practice Course, BPP Law School, London
  • 2009 – Graduate Diploma in Law, Oxford Brookes University
  • 2008 – BA (Hons) Physiological Sciences, University of Oxford
more less

Feed

30/01/2024
What’s in a name? Updated EMA guideline on naming medicinal products processed...
The updated EMA Guideline on the acceptability of names for human medicinal products processed through the centralised procedure was adopted by CHMP in December 2023 and came into effect on 1 January...
18/05/2023
In View: The Unified Patents Court and the Unitary Patent – are you ready?
CMS are delighted to invite you to the next instalment of our Life Sciences & Healthcare update webinar, where experts from across the firm will discuss key industry topics impacting, innovating and disrupting...
20/03/2023
Out with the old, in with the new? Considerations for patentees in opting...
So far in this series of blog posts, we began with an article that highlighted some of the key changes between the current European system of patent prosecution and enforcement and the new Unitary Patent...
08/03/2023
Out with the old, in with the new? Procedural features of the Unified Patent...
In our previous article, we looked at the current European system of patent prosecution and enforcement and highlighted some of the key changes that will be coming with the new Unitary Patent and Unified...
22/02/2023
The changing face of healthcare delivery – reducing environmental impact...
Since 2020, and as a natural consequence of the Covid-19 pandemic, the face of healthcare delivery has changed with the development of digital health and technology accelerating and the provision of remote...
22/02/2023
Out with the old, in with the new? Comparing the existing European Patent...
In this first of three articles, we compare the current European system of patent prosecution and enforcement with the new Unitary Patent and Unified Patent Court which will come into effect on 1 June...
21/02/2023
The changing face of healthcare delivery – reducing environmental impact...
Since 2020, and as a natural consequence of the Covid-19 pandemic, the face of healthcare delivery has changed with the development of digital health and technology accelerating and the provision of remote healthcare and online prescribing expanding exponentially.
21/10/2022
New MHRA roadmap for Software and AI as a medical device
On 17 October 2022, the MHRA published a “roadmap” for its Software and AI as a Medical Device Change Programme. The roadmap The Change Programme was originally published in 2021, setting out a promise...
12/10/2022
MHRA extends European Commission Decision Reliance Procedure to 31 December...
On 30 September 2022, the Medicines and Healthcare products Regulatory Agency (MHRA) announced that the European Commission Decision Reliance Procedure (ECDRP) has been extended by 12 months to 31 December...
15/09/2022
Pharmaceutical advertising regulation and medical device advertising in...
1. Which laws are applicable regarding advertising of medicines and medical devices? 1.1 Medicinal Products The key UK statute regulating ad­vert­ising/pro­mo­tion of medicines is the Human Medicines Regulations...
23/02/2021
Life Sciences Quarterly Update - Brexit Implications for the MedTech Sector
We are delighted to invite you to our life sciences quarterly update webinar, ‘in view’. Our CMS team will be evaluating the wide ranging impacts of Brexit for those operating in the MedTech sector...
29/10/2020
EU General Court clarifies interpretation of “satisfactory method” in the...
In the recent case of Medac Gesellschaft für klinische Spezi­al­prä­par­ate mbH v European Commission, the EU General Court has annulled a decision of the European Commission in which it held that the applicant’s...